Navigation Links
Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Date:2/23/2011

ive diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
(Date:10/17/2014)... , Oct. 17, 2014 The ... Medical Technology Policy: The Green Park ... FDA, public and private payers, medical device and ... and other experts January 12, 2015 at its ... value of weight loss treatments.  Participants will discuss ...
(Date:10/17/2014)... , Oct. 17, 2014  China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that the Company has received approval from the ... commercial manufacturing of human prothrombin complex concentrate ("PCC") ... Shandong Taibang,s new coagulation factor production facility for ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... cells in bone marrow supply,leukemic cells with the ... is depleted by the cancer drug,asparaginase, MEMPHIS, Tenn., ... fails to help cure some children with acute,lymphoblastic ... the bone marrow counteract the effect of that ...
... in Gene Activity and Metabolic,Enzymes Show How Cells Respond ... a Key Player in the Daily Biochemical Routines that,Support ... at,St. Jude Children's Research Hospital have mapped out many ... a cell's,response to a shortage of a molecule called ...
Cached Medicine Technology:Leukemic Cells Find Safe Haven in Bone Marrow 2Leukemic Cells Find Safe Haven in Bone Marrow 3Study Shows Metabolic Strategy of Stressed Cell 2Study Shows Metabolic Strategy of Stressed Cell 3
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... Metropolitan Health Plan (MHP(R)),the HMO of Hennepin County, announced ... Financial Officer and David R. Johnson,Executive Director., David ... for over 35,years. During his tenure at MHP, the ... Assistance, to a plan that offers 10 government,sponsored plans ...
... A key protein change can lessen the cholesterol-lowering drugs, ... genetic quirk in the production of one protein helps ... benefit of statin drugs, researchers report. , Statins include ... , The protein, abbreviated as HMGCR, plays a critical ...
... Many women experience menopausal changes in their body ... they don,t notice can be more dangerous. In a ... discovered significant changes in the brain,s vascular system when ... currently used estrogen-based hormone therapies may complicate this process ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received final approval from the U.S. Food ... Application (ANDA) for Venlafaxine,Hydrochloride (HCl) Tablets 25 mg ... (base) and 100 mg (base)., Venlafaxine HCl ...
... 16 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD), is pleased to ... shareholders of its outstanding preferred shares. The,dividend declared is ... quarterly. Each preferred share was sold at $25 per ... Fund Corp., The dividend is payable August 31, ...
... studies evaluating dietary changes and complementary medicine for the ... at Rush University Medical Center. Funded by the ... the impact of mind/body medicine on patients suffering from ... diet impacts patients with Crohn,s Disease. , ...
Cached Medicine News:Health News:Metropolitan Health Plan Announces Senior Management Appointments 2Health News:Research Shows Why Statins Don't Work for Everyone 2Health News:Complex changes in the brain's vascular system occur after menopause 2Health News:MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares. 2Health News:Study underway to find an alternative cure for Crohn's disease and ulcerative colitis 2
... -4C. 5.5 Cubic Ft. ... light. Manual push button ... Two shelves. In-door shelves ... thermostat. Magnetic gasket. Hermetically ...
Designed to meet the requirements of reagent grade water for routine analysis....
... Needs, Synergy systems produce ultrapure water from pre-treated ... 1.2 L/min to meet the basic needs of ... dual-wavelength UV lamp (185 nm and 254 nm) ... contaminants (< 5 ppb TOC when fed by ...
... mechanism for speed, stability and durability. ... display modes, multiple units of measure, ... auto print, and GLP/GMP/ISO output including ... clock. Touch-key calibration with external weights ...
Medicine Products: